Inuvair Nexthaler (Formoterol Fumarate Dihydrate, Beclometasone Dipropionate Anhydrous)

Beclometasone dipropionate acts as an inhaled corticosteroid, binding to glucocorticoid receptors and suppressing inflammatory gene expression in the airways. Formoterol fumarate is a long‑acting beta2‑adrenergic agonist that stimulates beta2 receptors, increasing cyclic AMP and causing smooth‑muscle relaxation for sustained bronchodilation. Together they provide anti‑inflammatory and bronchodilatory effects.

The dose of Inuvair Nexthaler is determined by the prescribing clinician based on the severity of the patient’s asthma or COPD, age, and response to therapy. The prescriber will specify the number of inhalations per day and any step‑wise adjustments needed for optimal disease control.

The pregnancy category for Inuvair Nexthaler is not definitively established. It should only be used during pregnancy or lactation if the potential therapeutic benefit justifies any potential risk to the fetus or infant. Healthcare providers should discuss individual risk factors with the patient.

To order Inuvair Nexthaler, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and required import documentation.

Inuvair Nexthaler combines an inhaled corticosteroid (beclometasone) with a long‑acting beta2‑agonist (formoterol), similar to other combination inhalers such as budesonide/formoterol or fluticasone/salmeterol. Its dry‑powder inhaler format offers breath‑actuated delivery without propellants, which some patients prefer for ease of use and reduced coordination requirements.

Store Inuvair Nexthaler at ambient temperature below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Keep the inhaler out of reach of children and do not expose it to extreme heat or humidity, which could affect the powder’s integrity.

To use Inuvair Nexthaler, the patient should first exhale fully away from the device, then place the mouthpiece between the lips, inhale quickly and deeply through the mouth, and hold the breath for a few seconds before exhaling. The inhaler is breath‑actuated, so no manual actuation is required.

Serious risks include paradoxical bronchospasm, adrenal suppression with prolonged high‑dose use, pneumonia (particularly in COPD patients), cardiac arrhythmias or tachycardia, severe hypersensitivity reactions such as anaphylaxis, and osteoporosis with long‑term high‑dose corticosteroid exposure. Patients should seek immediate medical attention if they experience any of these events.

Inuvair Nexthaler is contraindicated in patients with a known hypersensitivity to beclometasone, formoterol, or any excipients in the inhaler. It should also be avoided in individuals who have experienced a severe allergic reaction to other inhaled corticosteroids or long‑acting beta2‑agonists. Patients with uncontrolled cardiovascular disease should use it only under close medical supervision.